Navigation Links
Knowledge of genetics improves uncertain medication
Date:2/19/2009

Roughly 100,000 Swedes are under treatment with the blood-thinning drug Waran. Patients evince varying sensitivity to Waran, which makes the initiation of treatment a risky balancing act between hemorrhaging and clotting. Now researchers at Uppsala University have developed a model for calculating the appropriate dose before treatment starts. The study appears in the scientific publication New England Journal of Medicine.

Some 20 research teams in four regions of the world have joined together to study whether it is possible to determine the proper dosage of Waran before starting treatment. Data from 5,700 subjects undergoing treatment with Waran were collected from the four parts of the globe. Niclas Eriksson, a statistician at UCR Uppsala Clinical Research Center has developed a model for calculating the right dosage of Waran for individuals of European, African, and Asian origin.

"The findings show that with the aid of two genes, VKORC1 and CYP2C9, it is possible to predict what dosage patients will land at," says Niclas Eriksson.

"Almost half of patients have mutations that entail that they need a slightly lower dose than normal, and a small percentage need a much lower dose," says Mia Wadelius, a physician and researcher in clinical pharmacology, Uppsala University Hospital, who was in charge of collecting the data in Sweden.

The next step will be to test this method on patients in health care. This spring an American clinical test will get underway to study whether custom-tailored treatment increases the certainty in treating patients with Waran. Similar clinical testing will start this autumn in seven countries in Europe. A total of 3,000 patients who are starting treatment with blood-thinning medicines will be recruited. The Swedish part of the study will be directed by Mia Wadelius, and the Waran clinics in Uppsala and Skne will be participating. Patients will start either with a custom-tailored dosage or with the normal dosage and then be compared.

"Even patients receiving a tailored dose need regular tests of the blood's ability to coagulate, since diet and other medicines play a role, but it is our hope that the treatment will be both safer and more secure with tailored dosage," says Mia Wadelius.


'/>"/>

Contact: Mia Wadelius
Mia.Wadelius@medsci.uu.se
46-018-611-4945
Uppsala University
Source:Eurekalert

Related medicine news :

1. Survey reveals disparities in skin cancer knowledge, protection among high school students
2. Health Knowledge Empowers the Public
3. ER episode impacts viewers health knowledge and behavior
4. ER episode impacts viewers health knowledge and behavior
5. Eclipsys Knowledge-Based Charting Helps Health First Improve Patient-Care Outcomes
6. Americans Knowledge of Fats Growing But Still Insufficient
7. Gauging parent knowledge about teens substance use
8. Education program leads to lasting improvement of cancer knowledge in African Americans
9. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
10. Education program leads to lasting improvement of cancer knowledge in African-Americans
11. Final of EPSRCs 2007 Knowledge Transfer Challenge Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused ... half the issue representing international (non-US) based authors, the third volume of PXJ ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life ... better understand life insurance throughout various life stages. , The site launched on ... needs calculator and content specific to the times when life insurance matters most. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... for the 2016 Main Residency Match® (“the Match”), the system through which U.S. ... teaching institutions. A record-high 30,750 positions were placed in the 2016 Match, and ...
(Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
Breaking Medicine Technology: